Since then, it has received FDA approval for the treatment of adults with cardiovascular risks and type 2 diabetes, as well as being the only GLP-1 receptor agonist to reduce the risk of worsening kidney disease and cardiovascular death in users
You have a history of liver, kidney, or blood-related conditions
According to FDA prescribing information, gastrointestinal adverse effects vary by medication and dose, typically occurring in 15-45% of patients, particularly during dose escalation
It correlates with the rate and amount of weight loss
Focus on Bland, Easy-to-Digest Foods When nausea is active, particularly in those first few days after injections, stick with gentle foods
[1] Results from Clinical Trials The good news is that clinical studies show that Wegovy can lead to significant weight loss and important health benefits beyond the scale